Scrying Biotech
Long only, biotech, micro-cap, small-cap

MediciNova: Gestation Is Slow And Uncomfortable - Birth Is Sudden And Unexpected

Executive summary:

  • MediciNova has an important proof-of-concept catalyst on the horizon for its lead compound, MN-166, or Ibudilast as a treatment for opioid dependency.
  • Ibudilast has already been shown to have effect in the treatment of methamphetamine addiction exacting $23B annually from the U.S. economy relative to crime, lost work productivity and healthcare.
  • Already having received "fast-track" status in this indication, MediciNova is now in consultation with the FDA to advance this molecule as quickly as possible into commercialization.
  • MediciNova also recently received a milestone payment equaling eight months of operating capital for its contribution to Genzyme's gene therapy treatment in Parkinson's disease which should relieve downward pressure on the stock.


Biotechnology companies are by and large birthed through...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details